Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a...

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Pharmacology

Background:

• Placenta previa is a significant risk factor for preterm labor and associated neonatal complications.
• Rising cesarean section rates have correlated with an increased incidence of placenta previa.
• Effective and safe tocolytic agents for managing placenta previa remain to be fully established.

Purpose of the Study:

• To evaluate the efficacy of 17α-hydroxyprogesterone caproate (17α-OHP-C) in reducing preterm delivery (PTD) among women diagnosed with placenta previa.
• To assess the impact of 17α-OHP-C on bleeding attacks, gestational age at birth, and neonatal birth weight in this patient population.

Main Methods:

• A randomized controlled trial involving 114 women with placenta previa between 24 and 28 weeks of gestation.
• Participants were assigned to receive either weekly intramuscular injections of 17α-OHP-C (250 mg) until 37 weeks or no 17α-OHP-C treatment.
• Outcomes measured included rates of PTD, gestational age, number of bleeding attacks, and birth weight.

Main Results:

• The 17α-OHP-C group showed a significantly lower percentage of preterm delivery (approximately 37%) compared to the control group (63.5%, p=0.004).
• Mean gestational age was significantly longer in the 17α-OHP-C group (36.7 ± 0.7 weeks vs. 34.9 ± 1.2 weeks, p<0.000).
• Patients receiving 17α-OHP-C experienced fewer bleeding attacks and had higher mean birth weights (2841 ± 159 g vs. 2561 ± 168 g, p<0.000).

Conclusions:

• Maintenance tocolysis with intramuscular 17α-OHP-C is beneficial for women with placenta previa.
• The treatment effectively reduces bleeding episodes, the incidence of preterm delivery, and neonatal intensive care unit admissions.
• 17α-OHP-C demonstrates potential as an effective, safe, and well-tolerated tocolytic agent for placenta previa, warranting further large-scale investigation.